Group One Trading
KPTI icon

Group One Trading’s Karyopharm Therapeutics KPTI Stock Holding History

Group One Trading’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$828K Buy
148,700
+70,200
+89% +$535K ﹤0.01% 2887
2025
Q4 		$578K Buy
78,500
+44,700
+132% +$273K ﹤0.01% 3364
2025
Q3 		$221K Buy
33,800
+30,100
+814% +$162K ﹤0.01% 4572
2025
Q2 		$15.9K Buy
3,700
+2,400
+185% +$11.8K ﹤0.01% 6414
2025
Q1 		$4.86K Buy
1,300
+1,213
+1,394% +$10.4K ﹤0.01% 6661
2024
Q4 		$879 Buy
87
+34
+64% +$411 ﹤0.01% 6915
2024
Q3 		$664 Sell
53
-134
-72% -$1.67K ﹤0.01% 6361
2024
Q2 		$2.43K Sell
187
-1,540
-89% -$25.5K ﹤0.01% 6167
2024
Q1 		$39.1K Buy
+1,727
New +$30.3K ﹤0.01% 4918
2023
Q4 		– Sell
-987
Closed -$19.8K – 7793
2023
Q3 		$19.8K Buy
987
+114
+13% +$2.56K ﹤0.01% 5886
2023
Q2 		$23.4K Buy
873
+240
+38% +$10.3K ﹤0.01% 5879
2023
Q1 		$37K Sell
633
-1,040
-62% -$51.3K ﹤0.01% 5074
2022
Q4 		$85.3K Buy
1,673
+746
+80% +$51.7K ﹤0.01% 4565
2022
Q3 		$76K Sell
927
-1,940
-68% -$145K ﹤0.01% 5043
2022
Q2 		$194K Sell
2,867
-1,226
-30% -$112K ﹤0.01% 4341
2022
Q1 		$453K Sell
4,093
-8,294
-67% -$1.03M ﹤0.01% 3916
2021
Q4 		$1.2M Buy
12,387
+7,020
+131% +$700K ﹤0.01% 3172
2021
Q3 		$469K Buy
5,367
+1,054
+24% +$109K ﹤0.01% 4261
2021
Q2 		$668K Sell
4,313
-1,047
-20% -$152K ﹤0.01% 3891
2021
Q1 		$846K Sell
5,360
-1,327
-20% -$280K ﹤0.01% 3427
2020
Q4 		$1.55M Buy
6,687
+940
+16% +$218K ﹤0.01% 2257
2020
Q3 		$1.26M Buy
5,747
+1,840
+47% +$450K ﹤0.01% 1989
2020
Q2 		$1.11M Buy
3,907
+827
+27% +$245K 0.01% 1928
2020
Q1 		$888K Buy
3,080
+1,540
+100% +$425K 0.01% 1615
2019
Q4 		$443K Sell
1,540
-1,040
-40% -$226K ﹤0.01% 2530
2019
Q3 		$372K Buy
2,580
+2,247
+675% +$305K ﹤0.01% 2587
2019
Q2 		$30K Sell
333
-234
-41% -$18.8K ﹤0.01% 4021
2019
Q1 		$50K Buy
567
+500
+746% +$55.4K ﹤0.01% 3567
2018
Q4 		$9K Buy
+67
New +$11.3K ﹤0.01% 4304
2018
Q3 		– Sell
-220
Closed -$56K – 5399
2018
Q2 		$56K Buy
220
+187
+567% +$46.3K ﹤0.01% 3889
2018
Q1 		$7K Buy
+33
New +$6.58K ﹤0.01% 4419
2017
Q4 		– Sell
-33
Closed -$5K – 5020
2017
Q3 		$5K Buy
+33
New +$4.73K ﹤0.01% 4478
2017
Q2 		– Sell
-33
Closed -$6K – 4911
2017
Q1 		$6K Hold
33
– – ﹤0.01% 4243
2016
Q4 		$5K Sell
33
-767
-96% -$104K ﹤0.01% 4095
2016
Q3 		$117K Sell
800
-120
-13% -$14.4K ﹤0.01% 2836
2016
Q2 		$93K Buy
920
+607
+194% +$78.9K ﹤0.01% 2915
2016
Q1 		$42K Sell
313
-1,374
-81% -$152K ﹤0.01% 3353
2015
Q4 		$335K Buy
1,687
+1,394
+476% +$302K ﹤0.01% 2123
2015
Q3 		$46K Sell
293
-1,107
-79% -$296K ﹤0.01% 3576
2015
Q2 		$571K Sell
1,400
-33
-2% -$14.3K 0.01% 1665
2015
Q1 		$658K Buy
1,433
+1,373
+2,288% +$592K 0.01% 1395
2014
Q4 		$34K Sell
60
-473
-89% -$269K ﹤0.01% 3638
2014
Q3 		$280K Buy
+533
New +$301K ﹤0.01% 2098

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Group One Trading's KPTI Position: Q1 2026 in Review

Group One Trading increased its Karyopharm Therapeutics (KPTI) stake by 87% in Q1 2026, buying an estimated $679K and bringing the position to 191,527 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2646.

Group One Trading first reported a position in KPTI in Q3 2014 and has held it in 27 quarters since. The position peaked at $1.31M in Q4 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Group One Trading held 191,527 shares of Karyopharm Therapeutics worth $1.07M as of Q1 2026.
  • Group One Trading bought 89,108 Karyopharm Therapeutics shares in Q1 2026, an estimated $679K.
  • Karyopharm Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2646 holding.
  • Group One Trading first reported a position in Karyopharm Therapeutics in Q3 2014 and has held it in 27 quarters since.
  • Group One Trading's Karyopharm Therapeutics position peaked at $1.31M in Q4 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.